A Phase 2 study of Ivonescimab plus chemotherapy in thymic cancer
Not Yet Recruiting Phase 2 NCT06750952
Study Description
Evaluating the effectiveness and safety of Ivonescimab combined with chemotherapy as a first-line treatment for relapsed or metastatic thymic cancer
Study Details
- Registry ID:
- NCT06750952
- Conditions:
- Relapsed or Metastatic Thymic Cancer, First-line Treatment
- Phase:
- Phase 2
- Target Enrollment:
- 24 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.